- 4-8 months for standard chemotherapy, varies for CAR-T
- Weeks between chemotherapy cycles, 1-3 months for CAR-T recovery
- 91%
China versus the U.S.
- China clinical rate
- $5,000 – $45,000
- $25,000
- United States
- $30,000 – $500,000
- $265,000
- You save
- ~91%
- $240,000 per procedure
Prices are approximate ranges. Actual cost depends on hospital, surgeon, materials, and case complexity.
What the procedure involves.
China's hematology-oncology centers provide comprehensive lymphoma treatment including R-CHOP and other immunochemotherapy regimens, CAR-T cell therapy for relapsed disease, and autologous stem cell transplant. China is a global leader in CAR-T therapy with multiple domestically approved products at a fraction of Western pricing. Patients with both Hodgkin and non-Hodgkin lymphoma benefit from multidisciplinary care and access to cutting-edge treatments.
Step by step.
Diagnosis & Subtyping
Excisional biopsy with immunohistochemistry, flow cytometry, and molecular studies classify lymphoma subtype
Staging PET-CT
Full-body PET-CT and bone marrow biopsy determine disease stage and treatment approach
Immunochemotherapy
Standard regimen (R-CHOP for DLBCL, ABVD for Hodgkin) delivered in 6-8 cycles
Response Assessment & Consolidation
Interim and end-of-treatment PET-CT; CAR-T or stem cell transplant for refractory disease
- Access to affordable CAR-T therapy ($40-60K vs $400-500K in US)
- Multiple China-approved CAR-T products for B-cell lymphomas
- High cure rates for many lymphoma subtypes
- Comprehensive supportive care during intensive treatment
- Immunosuppression increasing infection risk
- Chemotherapy-induced cardiotoxicity (doxorubicin)
- CAR-T cytokine release syndrome (CRS)
- Secondary cancers from chemotherapy or radiation
Ask the AI for hospitals that handle lymphoma treatment.
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.